Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase

Dear colleagues,

CSHP has been invited by the Bruyère Research Institute/Deprescribing Guidelines in the Elderly Project from Canada, in collaboration with the University of Sydney’s NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People from Australia, to comment on the Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia. The purpose of this guideline is to assist healthcare professionals in determining when it might be suitable to trial withdrawal of these medications for an individual and to guide how to conduct withdrawal. The guideline has been primarily developed for use in Australia and Canada (Australian spelling and terminology are used throughout the guideline).

A draft of the guideline and supporting documents are available from: http://sydney.edu.au/medicine/cdpc/news-events-participation/deprescribing-guideline.php. To streamline the response and review process, please submit your feedback using the attached form.

Please send your comments by Tuesday, July 4, 2017 to Cathy Lyder, CSHP's Director, Members and Programs, at clyder@cshp.ca

Project Files